CN104414999A - Anti-tumor targeted nanometer drug-loaded microcapsule preparation method - Google Patents
Anti-tumor targeted nanometer drug-loaded microcapsule preparation method Download PDFInfo
- Publication number
- CN104414999A CN104414999A CN201310361675.4A CN201310361675A CN104414999A CN 104414999 A CN104414999 A CN 104414999A CN 201310361675 A CN201310361675 A CN 201310361675A CN 104414999 A CN104414999 A CN 104414999A
- Authority
- CN
- China
- Prior art keywords
- drug
- poly
- benzyl
- serine
- phosphatidylcholine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 35
- 229940079593 drug Drugs 0.000 title claims abstract description 26
- 239000003094 microcapsule Substances 0.000 title claims abstract description 24
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 230000000259 anti-tumor effect Effects 0.000 title abstract 2
- 229920000642 polymer Polymers 0.000 claims abstract description 33
- 239000000693 micelle Substances 0.000 claims abstract description 23
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims abstract description 21
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims abstract description 17
- IDGQXGPQOGUGIX-VIFPVBQESA-N O-BENZYL-l-SERINE Chemical compound OC(=O)[C@@H](N)COCC1=CC=CC=C1 IDGQXGPQOGUGIX-VIFPVBQESA-N 0.000 claims abstract description 15
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims abstract description 14
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229920001400 block copolymer Polymers 0.000 claims abstract description 10
- 229960000304 folic acid Drugs 0.000 claims abstract description 10
- 235000019152 folic acid Nutrition 0.000 claims abstract description 10
- 239000011724 folic acid Substances 0.000 claims abstract description 10
- 238000000034 method Methods 0.000 claims abstract description 9
- 238000000502 dialysis Methods 0.000 claims abstract description 7
- 239000000463 material Substances 0.000 claims abstract description 7
- 238000010560 atom transfer radical polymerization reaction Methods 0.000 claims abstract description 4
- -1 O-benzyl-L-serine carboxylic anhydride Chemical class 0.000 claims abstract description 3
- 230000000118 anti-neoplastic effect Effects 0.000 claims description 17
- 238000006243 chemical reaction Methods 0.000 claims description 16
- 230000015572 biosynthetic process Effects 0.000 claims description 11
- 238000003786 synthesis reaction Methods 0.000 claims description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 10
- 150000007857 hydrazones Chemical class 0.000 claims description 8
- 239000003999 initiator Substances 0.000 claims description 8
- TZRXHJWUDPFEEY-UHFFFAOYSA-N Pentaerythritol Tetranitrate Chemical compound [O-][N+](=O)OCC(CO[N+]([O-])=O)(CO[N+]([O-])=O)CO[N+]([O-])=O TZRXHJWUDPFEEY-UHFFFAOYSA-N 0.000 claims description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 6
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 claims description 6
- 150000001345 alkine derivatives Chemical group 0.000 claims description 6
- 229960004679 doxorubicin Drugs 0.000 claims description 6
- 230000002209 hydrophobic effect Effects 0.000 claims description 6
- 229920002521 macromolecule Polymers 0.000 claims description 6
- NWXMGUDVXFXRIG-WESIUVDSSA-N (4s,4as,5as,6s,12ar)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O NWXMGUDVXFXRIG-WESIUVDSSA-N 0.000 claims description 5
- 229930195573 Amycin Natural products 0.000 claims description 5
- 239000000178 monomer Substances 0.000 claims description 5
- 108010000222 polyserine Proteins 0.000 claims description 5
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 claims description 4
- 238000005859 coupling reaction Methods 0.000 claims description 4
- 238000006116 polymerization reaction Methods 0.000 claims description 4
- 125000005133 alkynyloxy group Chemical group 0.000 claims description 3
- 229920001577 copolymer Polymers 0.000 claims description 3
- 230000008878 coupling Effects 0.000 claims description 3
- 238000010168 coupling process Methods 0.000 claims description 3
- 125000003929 folic acid group Chemical group 0.000 claims description 3
- YHHSONZFOIEMCP-UHFFFAOYSA-O phosphocholine Chemical compound C[N+](C)(C)CCOP(O)(O)=O YHHSONZFOIEMCP-UHFFFAOYSA-O 0.000 claims description 3
- 229950004354 phosphorylcholine Drugs 0.000 claims description 3
- 229960004132 diethyl ether Drugs 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 238000010462 azide-alkyne Huisgen cycloaddition reaction Methods 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 11
- 239000003937 drug carrier Substances 0.000 abstract description 10
- 230000000694 effects Effects 0.000 abstract description 7
- 206010028980 Neoplasm Diseases 0.000 abstract description 5
- 230000008901 benefit Effects 0.000 abstract description 5
- 201000011510 cancer Diseases 0.000 abstract description 5
- 238000001914 filtration Methods 0.000 abstract description 5
- 238000011068 loading method Methods 0.000 abstract description 5
- 210000000056 organ Anatomy 0.000 abstract description 5
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 abstract description 4
- 238000004108 freeze drying Methods 0.000 abstract description 3
- 230000008685 targeting Effects 0.000 abstract description 3
- 239000002105 nanoparticle Substances 0.000 abstract description 2
- 238000007151 ring opening polymerisation reaction Methods 0.000 abstract description 2
- 229940009456 adriamycin Drugs 0.000 abstract 1
- 238000001311 chemical methods and process Methods 0.000 abstract 1
- 239000011258 core-shell material Substances 0.000 abstract 1
- 238000012377 drug delivery Methods 0.000 abstract 1
- 239000012528 membrane Substances 0.000 abstract 1
- 239000008213 purified water Substances 0.000 abstract 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 238000011160 research Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000001291 vacuum drying Methods 0.000 description 6
- 239000011259 mixed solution Substances 0.000 description 5
- 125000003118 aryl group Chemical group 0.000 description 4
- 238000004062 sedimentation Methods 0.000 description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 239000000385 dialysis solution Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 229960001866 silicon dioxide Drugs 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 description 2
- 229910021589 Copper(I) bromide Inorganic materials 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- NKNDPYCGAZPOFS-UHFFFAOYSA-M copper(i) bromide Chemical compound Br[Cu] NKNDPYCGAZPOFS-UHFFFAOYSA-M 0.000 description 2
- WVIIMZNLDWSIRH-UHFFFAOYSA-N cyclohexylcyclohexane Chemical compound C1CCCCC1C1CCCCC1 WVIIMZNLDWSIRH-UHFFFAOYSA-N 0.000 description 2
- 239000000412 dendrimer Substances 0.000 description 2
- 229920000736 dendritic polymer Polymers 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000005374 membrane filtration Methods 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 238000001338 self-assembly Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 229920002818 (Hydroxyethyl)methacrylate Polymers 0.000 description 1
- HUTXVUPGARJNHM-UHFFFAOYSA-N 1-(2-chloroethoxy)ethanol Chemical compound CC(O)OCCCl HUTXVUPGARJNHM-UHFFFAOYSA-N 0.000 description 1
- ROFVEXUMMXZLPA-UHFFFAOYSA-N Bipyridyl Chemical group N1=CC=CC=C1C1=CC=CC=N1 ROFVEXUMMXZLPA-UHFFFAOYSA-N 0.000 description 1
- 102100035024 Carboxypeptidase B Human genes 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 241000555268 Dendroides Species 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 229910052688 Gadolinium Inorganic materials 0.000 description 1
- 101000946524 Homo sapiens Carboxypeptidase B Proteins 0.000 description 1
- 238000006736 Huisgen cycloaddition reaction Methods 0.000 description 1
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
- DXRFZHILMCWCNG-UHFFFAOYSA-N N,N-dimethyl-1,8-naphthyridin-2-amine Chemical compound C1=CC=NC2=NC(N(C)C)=CC=C21 DXRFZHILMCWCNG-UHFFFAOYSA-N 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- WUESWDIHTKHGQA-UHFFFAOYSA-N cyclohexylurea Chemical compound NC(=O)NC1CCCCC1 WUESWDIHTKHGQA-UHFFFAOYSA-N 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- SEACYXSIPDVVMV-UHFFFAOYSA-L eosin Y Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C([O-])=C(Br)C=C21 SEACYXSIPDVVMV-UHFFFAOYSA-L 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000004992 fission Effects 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 238000007306 functionalization reaction Methods 0.000 description 1
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000002114 nanocomposite Substances 0.000 description 1
- 239000002086 nanomaterial Substances 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- UKODFQOELJFMII-UHFFFAOYSA-N pentamethyldiethylenetriamine Chemical compound CN(C)CCN(C)CCN(C)C UKODFQOELJFMII-UHFFFAOYSA-N 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920000141 poly(maleic anhydride) Polymers 0.000 description 1
- 108010064470 polyaspartate Proteins 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 239000004632 polycaprolactone Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- YORCIIVHUBAYBQ-UHFFFAOYSA-N propargyl bromide Chemical compound BrCC#C YORCIIVHUBAYBQ-UHFFFAOYSA-N 0.000 description 1
- 238000010526 radical polymerization reaction Methods 0.000 description 1
- 229920005604 random copolymer Polymers 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention discloses an anti-tumor targeted nanometer drug-loaded microcapsule preparation method, which comprises: adopting an atom transfer radical polymerization method to polymerize phosphatidyl choline to obtain poly phosphatidyl choline; modifying the poly phosphatidyl choline with folic acid molecules; adopting a ring-opening polymerization method to polymerize O-benzyl-L-serine carboxylic anhydride to obtain poly O-benzyl-L-serine; grafting adriamycin on the poly O-benzyl-L-serine through a hydrazone bond; bonding the poly phosphatidyl choline and the poly O-benzyl-L-serine through a click chemistry method to obtain a block copolymer; respectively dissolving the block polymer in tetrahydrofuran, transferring into a dialysis bag, carrying out dialysis with purified water, and filtering the dialyzed solution with a filtration membrane; and carrying out freeze-drying on the filtered solution to obtain the drug-loaded micelles, wherein the drug carrier micelles have a core-shell double-layer structure, the outer layer is the hydrophilic poly phosphatidyl choline, and the inner layer is the drug molecule wrapping layer. According to the present invention, the material has the following advantages that: the material belongs to the nanoparticles; the targeted drug delivery on the cancer cells and the pH-sensitive drug release in the cancer cells can be achieved; the drug loading is high; the stability is good; and with the targeting function, the toxic-side effect of the drug on the normal tissues and organs can be effectively reduced.
Description
Technical field
The present invention relates to a kind of preparation method of antineoplastic target nano drug-carrying microcapsule, particularly relate to a kind of preparation method with the block macromolecular material pharmaceutical carrier micelle of cancer cell targeting.Belong to polymer chemistry and technical field of polymer.
Background technology
Cancer has become the main disease of harm humans health, and one of important means of Therapeutic cancer is Drug therapy, but many cancer therapy drugs also exist and are insoluble in the defect such as water, poor stability.As camptothecine, paclitaxel, amycin, 5-fluorouracil etc. are all difficult to because of poor solubility be utilized well by organism, solve the crux that its water solubility problems is this kind of pharmaceutical preparation clinical practice.In addition, oncotherapy and its effect of diagnostic medicine are nonselective mostly, and some normal structure organs often have more distribution, and under therapeutic dose, normal tissue organ toxic and side effects is large.Therefore solve how solubilising slightly solubility cancer therapy drug and increase medicine stability, improve the selectivity of cancerous cell extremely urgent.Therefore, finding a kind of reliable target medicine carrier is the key solving above two problems.
What macromolecule micelle pharmaceutical carrier generally adopted is all linear polymeric micelle.The research work that Bae seminar carries out is the most noticeable, and it points out in delivered research paper, is linked on main polymer chain by Dox key with hydrazone key, and utilizes pH in cancerous cell microenvironment to be that faintly acid makes hydrazone bond fission, achieves the target spot release of Dox.And, one section of paper (Bae Y, Jang W-D, Nishiyama N, Fukushima S, Kataoka K. that Bae delivered on Molecular BioSystems magazine in 2005
mol BioSyst2005; 1 (3): 242-250.), first simultaneously by Fol and Dox respectively key link PEG and PASP(poly-aspartate) on, thus having targeted delivery and the target spot release multifunctionality of medicine concurrently, Flow cytometry experiments (FCM) shows that cell is not significantly increased containing the polymer micelle of Fol the intake of polymer micelle.Gong Shaoqin seminar has also been engaged in similar research.It is with poly
caprolactone random copolymer is kernel, and PEG is shell, has prepared polymer nano micelle.Dox is connected with hydrazone key, and the PEG end group that utilized Fol to modify, prepare pH responsive type target drug-carrying micelle, test cellular uptake amount and cytotoxicity, prove that Dox discharges (Yang X, Grailer JJ, Pilla S fast due to the fracture of hydrazone key in acid condition, Steeber DA, Gong S.
bioconjugate Chem2010; 21 (3): 496-504.).
Although linear polymer micelle is as the carrier of poorly water soluble drugs, demonstrate huge advantage and potential passing in medicine process, but still there is micelle poor stability, solubilizing effect is not obvious, drug release rate is low problem.The drug loading of current polymer micelle can only reach about 5% usually, obtain higher drug loading very difficult.Research finds, polymer connects medicine monomer by chemical bond, can reach higher drug loading.And linear block copolymers load capacity is often on the low side, if but cross multikey to connect its micellar structure of drug molecule unstable again.And star-type polymer can overcome this deficiency.
Shanghai Communications University Yan De high mountain (Liu J, Pang Y, Huang W, Huang X, Meng L, Zhu X, Zhou Y, Yan D.
biomacromolecules2011; 12 (5): 1567-1577.) synthesize dendroid poly phosphate-polylactic-acid block copolymer and be applied to pharmaceutical carrier research, after parcel Dox, have obvious inhibitory action to HeLa cell.Another representative research is that Chinese University of Science and Technology Liu generation is brave, utilizes functionalization
the polymaleic anhydride star-type polymer modified with Fol and Dox prepared by cyclodextrin, and key has connected the gadolinium element to magnetic resonance effect sensitivity simultaneously, finds in mouse experiment, polymer micelle has obvious reinforcement (Liu T, Li X, Qian Y in the gathering at liver, kidney position, Hu X, Liu S.
biomaterials2012; 33 (8): 2521-2531.).
But because polymer architecture in star-type polymer is comparatively complicated, poor biocompatibility appears in prepared pharmaceutical carrier, drug encapsulation ability declines, the problems such as dendrimer surface drug macromolecule water-solubility reduction.In addition, dendrimer complex structure, synthesis cost is higher.These problems all limit the application of star-type polymer nano medicament carrying system.Therefore, no matter be property polymer or common star-type polymer pharmaceutical carrier, can not possess: target-oriented drug simultaneously, high drug carrying capacity, micellar structure is stablized, the pH sensitivity of target spot release, biocompatibility height these several plays the performance of most important effect to the clinical practice of polymer drug carrier system.
Summary of the invention
The object of the invention is the preparation method setting up a kind of antineoplastic target nano drug-carrying microcapsule, this pharmaceutical carrier microcapsule has the following advantages: belong to nanoparticle; Medicine can be realized to pH sensitivity release in cancerous cell targeted delivery and cancerous cell; Drug loading is large; Good stability; Its target function can effectively reduce medicine normal tissue organ toxic and side effects.
This micelle is a kind of star block copolymer with hydrophilic and hydrophobic block; Can by amycin key connect with block polymer on; Macromolecular material has two hydrophilic segments, a hydrophobic segment: its hydrophilic section of macromolecular material is poly-phosphatidylcholine, is modified by folic acid.Hydrophobic section is polyserine, by hydrazone keyed jointing branch amycin; High molecular micellar structure has nucleocapsid double-decker, outer gathers phosphatidylcholine for hydrophilic, and internal layer is drug molecule integument.
Described block polymer is the polymer in following structural formula:
The technology of preparing scheme of pharmaceutical carrier microcapsule is as follows:
1) nitrine micromolecule initiator is prepared
2) synthesis of folic acid-NHS molecule
3) atom transfer radical polymerization and the modified with folic acid of Phosphorylcholine is gathered
4) both arms alkynes end group gathers the synthesis of O-benzyl-L-serine
5) Dox molecule is connected with the hydrazone key of poly-O-benzyl-L-serine
6) synthesis of star block copolymer
7) capsule of nano is prepared
Polymer nano micelle is prepared by dialysis.Concrete grammar is: after the star-type polymer of synthesis is dissolved in THF respectively, moves in bag filter, with 1000 mL pure water dialysis, refreshes the water periodically.After dialysis solution membrane filtration, lyophilization obtains copolymer carrier micelle.
By above technical scheme, tool of the present invention has the following advantages: 1) antineoplastic target nano drug-carrying microcapsule volume is little, has nanoscale structures, can pass through various barrier in human body;
2) antineoplastic target nano drug-carrying microcapsule critical micelle concentration is little, Stability Analysis of Structures;
3) antineoplastic target nano drug-carrying microcapsule load capacity is large, and good biocompatibility;
4) antineoplastic target nano drug-carrying microcapsule has Targeting delivery pharmic function, can effectively reduce medicine normal tissue organ toxic and side effects.
Accompanying drawing explanation
Fig. 1 is this high molecular structural representation;
Fig. 2 is the schematic diagram of this high molecule microcapsule;
Fig. 3 is the AFM scintigram of this high molecule microcapsule.
Detailed description of the invention
For making enforcement object of the present invention, technical scheme and advantage more clear, below in conjunction with the drawings and specific embodiments of the present invention, the present invention is described in detail:
As shown in Figure 1, be the chemical constitution schematic diagram of antineoplastic target nano drug-carrying microcapsule.This macromolecule is AB
22. type block macromolecular, have two hydrophilic section, and 3. a hydrophobic section formed.Key on each segment has connected different molecular structures:
Folic acid micromolecule 1. key is connected in poly-phosphatidylcholine molecules segment and 2. goes up, and is 2. prepared by Transfer Radical Polymerization;
3. the five-membered ring utilizing 1,3-Dipolar Cycloaddition to obtain and polyserine carry out coupling;
Utilize hydrazone key by segment 3. with Doxorubicin molecules 4. key link up.
As shown in Figure 2, a kind of antineoplastic target nano drug-carrying microcapsule is by this AB
2assorted arm star block macromolecular assembling is formed.Its structure is respectively by 1. folic acid micromolecule; 2. poly-phosphatidylcholine molecules; 3. polyserine; 4. the composition such as Doxorubicin molecules.Macromolecule is in aqueous by hydrophobic interaction, and can self assembly be spherical micellar structure, high molecular micellar structure has nucleocapsid double-decker:
Outer gather phosphatidylcholine 2. for hydrophilic;
Internal layer be polyserine 3., be drug molecule integument, internal layer can make drug molecule be wrapped in ball interior, thus realizes drug carrier function.
Figure 3 shows that AB
2assorted arm star block copolymer is the AFM scanogram of globular micelle structure that formed of self assembly in aqueous.Prove that macromolecule forms globular micelle structure homogeneous, good dispersion, does not reunite in aqueous, is conducive to realizing the delivery to drug molecule and release function.
Provide embodiment below to be specifically described the present invention; but it is worthy of note that following examples are only used to further illustrate the present invention; can not be interpreted as limiting the scope of the invention, some nonessential improvement that the person skilled in the art in this field makes the present invention according to the invention described above content and adjustment still belong to protection scope of the present invention.
Embodiment 1:
1. nitrine micromolecule initiator is prepared
Step one: 2-chloroethoxyethanol 5mL is dissolved in 25mL butanone, adds 4.5g NaN in solution
3, 2.5gBu
4nI, 10mg bicyclohexane also-hexaoxacyclooctadecane-6-6, mixture is heated to boiling, stir 24 hours.Filtered by mixture, precipitation acetone carries out cleaning down.The mixed solution obtained is the crude product of product, after mixed solution is concentrated, 90
oc carries out distillation and obtains pure substance.The 2-nitrine ethoxy ethanol obtained
1h NMR (CDCl
3):
3.70 (t, 2 H, C
h 2oH), 3.65 (t,
2h, HOCH
2c
h 2o), 3.56 (t, 2H, N
3cH
2c
h 2o), 3.37 (t, 2H, C
h 2n
3), and 2.56 (s, 1H, OH).
Step 2: by a kind of for step obtained 2-nitrine ethoxy ethanol 2g, alpha-chloro acyl chlorides 5.09g is dissolved in 30mL dichloromethane, reaction system is transferred in ice territory, is slowly added in reaction vessel by 6.8g dicyclohexylcarbodiimide, and stir.0.4g dimethylamino naphthyridine is dissolved in dichloromethane and instilled in reaction vessel in 10 minutes.Whole reaction system is 0
oreact 1 hour under C condition, then at room temperature react 24 hours.The cyclohexyl urea be precipitated out in course of reaction is filtered, and washs with dichloromethane.Extract with sodium bicarbonate solution (5%), then carry out drying with anhydrous magnesium sulfate.After reduced vacuum drying, be separated with silica gel chromatographic column, finally obtain product 2-chloro nitrine Ethoxyethane.
1H NMR (CDCl
3):
4.30 (t, 2H, CH
2OCO), 3.73 (t, 2H, COOCH
2C
H 2O), 3.67 (t, 2H, N
3CH
2C
H 2O), 3.35 (t, 2H, C
H 2N
3), and 1.92 (s, 6H, (CH
3)
2C)。
2. the synthesis of folic acid-NHS molecule
By 1.0g folic acid and 0. 495g N, N-dicyclohexylcarbodiimide (DCC) and 0. 463g N-hydroxysuccinimide (NHS) are dissolved in 20mL DMSO, at N
2the lower room temperature reaction 24h of protection, cross and filter byproduct of reaction N, N-dicyclohexyl urine (DCU), utilizes silica gel chromatographic column to be separated, can obtain folic acid-NHS molecule.
3. atom transfer radical polymerization and the modified with folic acid of Phosphorylcholine is gathered
By the 2-nitrine ethyoxyl bromo acid 12mg obtained in step 2, add methanol, bipyridyl and cuprous bromide with the 5.4g hydroxyethyl methacrylate phosphatidylcholine ratio be dissolved in simultaneously in 2:1:1 in 25mL DMSO.By bleeding-ventilate for three times-thaw cycles carries out tube sealing to polymerization pipe.Be polymerized after 24 hours, with methanol, polymer be precipitated out, filter, dry stand-by.Poly-phosphatidylcholine obtained by 2g is dissolved in 20mL dichloromethane, adds 2.8mL ethylenediamine, the terminal groups of poly-phosphatidylcholine is modified, obtain the polymer of end group band primary amine.The poly-phosphatidylcholine that 2g end group is modified is warming up to 50
oc reacts 6h.Reactant liquor is loaded bag filter (MWCO=3500) after having reacted, the 2 days free folic acid of removing afterwards of dialysing in deionized water, changes water every day 3 times.Dialysis solution ether sedimentation, vacuum drying obtains product.
4. both arms alkynes end group gathers the synthesis of O-benzyl-L-serine
Step one: 16.8g 3,5-methyl dihydroxy benzoate and 26.2g propargyl bromide are dissolved in 300mL acetone, add 15.1g sodium carbonate in the solution, 0.1g bicyclohexane also-hexaoxacyclooctadecane-6-6.Reaction solution is carried out be heated to backflow, react 24 hours.By sedimentation and filtration after reaction terminates, filtrate carries out concentrating under reduced pressure, in methanol, carry out recrystallization, obtains product 3,5-diacetylene p-methoxybenzoic acid methyl ester.
1H NMR in CDCl
3,
δ(ppm): 2.55 (2H,
CCH), 3.91(3H,
CH 3 O), 4.73 (4H,
CH 2 CCH), 6.82 (1H, aromatic), 7.29 (2H, aromatic)。
Step 2: 6.25g3,5-diacetylene p-methoxybenzoic acid methyl ester is dissolved in 30mL methanol, 73.9g ethylenediamine is dissolved in 120mL ethylenediamine, and 0
oslowly be added dropwise in reaction vessel under C condition, the process that drips needs 1 hours, and reaction 96 hours under room temperature again after being added dropwise to complete.Be less than 40
orevolve in the water-bath of C to steam and remove unnecessary solvent, utilizing the mixed solution of benzene/methanol (9/1 v/v) to carry out recrystallization to mixed solution, in vacuum drying oven, drying 24 hours, obtains product N-amine ethyl 3,5-diethyl alkynyloxy group aniline.
1H NMR in CDCl
3,
δ(ppm): 1.61 (2H,
CH
2 NH 2), 2.55 (2H,
CCH), 2.95 (2H,
CH 2NH
2), 3.49 (2H, CONH
CH 2), 4.73 (4H,
CH 2CCH), 6.68 (1H, CO
NH), 6.76 (1H, aromatic), 7.05 (2H, aromatic)。
Step 3: by the product N-amine ethyl 3 obtained in 0.16g step 2,5-diethyl alkynyloxy group aniline is as initiator, utilize ring-opening polymerisation mode polymer poly O-benzyl-L-serine carboxylic acid anhydrides 5.19g, monomer and initiator are added in polymerization pipe, and add dry DMF 15mL, react 24 hours under room temperature.Polymer absolute ether precipitates, dry 24 hours of vacuum drying oven.Obtain product both arms alkynes end group and gather O-benzyl-L-serine.
5. Doxorubicin molecules is connected with the hydrazone key of poly-O-benzyl-L-serine
The both arms alkynes end group obtained in 5.8mL hydrazine and 2.43g above-mentioned steps is gathered O-benzyl-L-serine to be dissolved in the dry DMF of 25mL, reaction system is heated to 40
oc, reacts 1 hour.Thick product absolute ether is precipitated, and by sedimentation and filtration, dry 24 hours of vacuum drying oven, obtains amido both arms alkynes end group and gathers O-benzyl-L-serine.This product 5g and 0.34g amycin monomer are dissolved in DMSO, reaction system is heated to 30
oc, react 48 hours, the reaction mixture absolute methanol obtained precipitates, and by sedimentation and filtration, dry 24 hours of vacuum drying oven.The poly-O-benzyl-L-serine of obtained Doxorubicin molecules grafting.
6. AB
2the synthesis of assorted arm star block copolymer
The poly-phosphatidylcholine modify 3.8g end group and the poly-O-benzyl-L-serine of 7.8g Doxorubicin molecules grafting are dissolved in 20mL dry DMF, and add 6.93mg PMDETA.Reaction system is carried out-ventilation-thaw cycles of bleeding for three times, add rapidly cuprous bromide 5.47mg.Reaction is 35
oreact 24 hours under C condition.React the mixed solution obtained and cross silicagel column to remove unnecessary mantoquita and other impurity.The concentrated later absolute methanol of solution precipitates, and finally obtains AB
2assorted arm star block copolymer.
7. the preparation of polymer nanocomposite microcapsule
Polymer nano micelle is prepared by dialysis.Concrete grammar is: after one or both star polymers are dissolved in THF respectively, moves in bag filter, with 1000 mL pure water dialysis, refreshes the water periodically.After dialysis solution membrane filtration, lyophilization obtains copolymer carrier micelle.
Finally it should be noted that, above embodiment is only in order to illustrate technical scheme of the present invention and unrestricted, although with reference to preferred embodiment to invention has been detailed description, those of ordinary skill in the art should understand, can a point technical scheme for invention be modified or be replaced on an equal basis, and not departing from the spirit and scope of technical solution of the present invention, it all should be encompassed in the middle of right of the present invention.
Claims (8)
1. an antineoplastic target nano drug-carrying microcapsule, its architectural feature is: described macromolecular material is the AB by two hydrophilic poly-phosphatidylcholine segments and the coupling of a hydrophobic poly-O-benzyl-L-serine segment
2type copolymer.
2. the method preparing antineoplastic target nano drug-carrying microcapsule according to claim 1 is carried out as follows:
1) for causing the synthesis of the nitrine micromolecule initiator of phosphatidylcholine monomer;
2) utilize folic acid micromolecule to carry out NHS activation, prepare folic acid-NHS molecule;
3) utilize the nitrine micromolecule initiator prepared by step 1), cause Phosphorylcholine micromolecule and carry out atom transfer radical polymerization, obtain poly-phosphatidylcholine, utilize folic acid-NHS molecular modification to gather phosphatidylcholine simultaneously;
4) both arms alkynes end group gathers the synthesis of O-benzyl-L-serine;
5) utilize Doxorubicin molecules to carry out grafting to poly-O-benzyl-L-serine, this reaction utilizes hydrazone key to connect;
6) click chemistry Reactive Synthesis star block copolymer is utilized;
7) polymer nano micelle is prepared by dialysis.
3. the preparation method of a kind of antineoplastic target nano drug-carrying microcapsule according to claim 2, is characterized in that solvent that in said method, synthesized by step 1), nitrine micromolecule initiator uses is any one in acetone, butanone, dioxane, acetonitrile.
4. the preparation method of a kind of antineoplastic target nano drug-carrying microcapsule according to claim 2, is further characterized in that the polymerization single polymerization monomer that in said method, step 4) uses is O-benzyl-L-serine carboxylic acid anhydrides.
5. the preparation method of a kind of antineoplastic target nano drug-carrying microcapsule according to claim 2, is further characterized in that the polymer coupling reaction that in said method, step 6) is carried out must adopt Huisgen 1,3-Dipolar Cycloaddition.
6. the preparation method of a kind of antineoplastic target nano drug-carrying microcapsule according to claim 2, is further characterized in that in said method and needs to adopt following micromolecule initiator:
1) 2-chloro nitrine Ethoxyethane,
2) N-amine ethyl 3,5-diethyl alkynyloxy group aniline.
7. antineoplastic target nano drug-carrying microcapsule according to claim 2, is further characterized in that: this macromolecular material is the star block copolymer formed by coupling by the poly-phosphatidylcholine segment of modified with folic acid and the polyserine of amycin grafting.
8. antineoplastic target nano drug-carrying microcapsule according to claim 2, is further characterized in that: described macromolecule micelle has nucleocapsid double-decker, outer gathers phosphatidylcholine for hydrophilic, and internal layer is drug molecule integument.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310361675.4A CN104414999A (en) | 2013-08-19 | 2013-08-19 | Anti-tumor targeted nanometer drug-loaded microcapsule preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310361675.4A CN104414999A (en) | 2013-08-19 | 2013-08-19 | Anti-tumor targeted nanometer drug-loaded microcapsule preparation method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104414999A true CN104414999A (en) | 2015-03-18 |
Family
ID=52965826
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310361675.4A Pending CN104414999A (en) | 2013-08-19 | 2013-08-19 | Anti-tumor targeted nanometer drug-loaded microcapsule preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104414999A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103989658A (en) * | 2014-04-30 | 2014-08-20 | 成都市绿科华通科技有限公司 | Preparation method for anti-tumor high-molecule-based medicine-carrying microcapsule |
| CN105968373A (en) * | 2016-05-16 | 2016-09-28 | 四川大学 | Zwitter-ion-contained multiple acid-sensitive anti-tumor drug-loading micelle and preparation method and application thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103059312A (en) * | 2012-12-12 | 2013-04-24 | 中科院广州化学有限公司 | Amphipathic ternary molecular brush polymer constructed multichannel nanocapsule |
-
2013
- 2013-08-19 CN CN201310361675.4A patent/CN104414999A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103059312A (en) * | 2012-12-12 | 2013-04-24 | 中科院广州化学有限公司 | Amphipathic ternary molecular brush polymer constructed multichannel nanocapsule |
Non-Patent Citations (2)
| Title |
|---|
| JI-HUN SEO ET.AL: "Surface tethering of phosphorylcholine groups onto poly(dimethylsiloxane) through swelling-deswelling methods with phospholipids moiety containing ABA-type block copolymers", 《BIOMATERIALS》 * |
| 汤继辉等: "聚氨基酸作为药物载体的研究进展", 《中国药科大学学报》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103989658A (en) * | 2014-04-30 | 2014-08-20 | 成都市绿科华通科技有限公司 | Preparation method for anti-tumor high-molecule-based medicine-carrying microcapsule |
| CN105968373A (en) * | 2016-05-16 | 2016-09-28 | 四川大学 | Zwitter-ion-contained multiple acid-sensitive anti-tumor drug-loading micelle and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104415010A (en) | Preparation method of antitumor micelle containing adriamycin | |
| CN104415013A (en) | Novel antitumor polymer drug containing adriamycin | |
| CN104415339A (en) | Self-assembled targeted nanometer drug carrier micelles | |
| CN104415342A (en) | Self-assembled drug carrier microcapsule system containing polypyrrolidone | |
| CN104415012A (en) | Preparation method of medical polymer drug | |
| CN104414999A (en) | Anti-tumor targeted nanometer drug-loaded microcapsule preparation method | |
| CN105169405A (en) | Preparation method of adriamycin polymer drug | |
| CN104415343A (en) | Self-assembled drug carrier microcapsule system containing polyacrylic acid | |
| CN104415344A (en) | Polymer drug microcapsule containing polyacrylic acid | |
| CN103977417A (en) | Preparation method of amphiphilic drug-loaded nanoparticles | |
| CN104415003A (en) | Polymer nano drug microcapsule containing polypyrrolidone | |
| CN103977418A (en) | Preparation method of doxorubicin-containing anti-tumor micelles | |
| CN104414996A (en) | Nano self-assembly drug carrier microcapsule system | |
| CN104434794A (en) | Novel adriamycin tumor cell inhibiting micelle preparation method | |
| CN104415002A (en) | Preparation method for antineoplastic high-molecular microcapsule | |
| CN104337767A (en) | Method for preparing pH sensitive drug carrier micelle | |
| CN104415011A (en) | Preparation method of cellular microenvironment pH-sensitive micelle | |
| CN104415007A (en) | Preparation method of tumor cell micro-environmentally responsive nano-micelle | |
| CN104337794A (en) | Intelligent amphiphilic targeting drug carrier system | |
| CN104415341A (en) | Preparation method of tumor cell micro-environmentally responsive targeted drug micelle | |
| CN104415004A (en) | Preparation method of biocompatible polymer antitumor drug | |
| CN103990140A (en) | Nanometer self-assembly drug carrier system | |
| CN103976977A (en) | Preparation of self-assembled polymer microcapsule system | |
| CN104415005A (en) | Novel anti-cancer polymer drug | |
| CN103977421A (en) | Preparation of high-molecular-based pH-sensitive medicament micelle |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20150318 |